Company intelligence / Profile preview
Extrinsic Immunity Therapeutics
Ann Arbor, Michigan, United Stateslinkedin.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing novel tools that leverage extrinsic immunity mechanisms to target cancers; recognized by Renaissance Ventures HotList in early 2025 indicating promising innovation trajectory [2]
- Therapeutic areas
- Oncology
- Modalities
- Targeted oncology therapeutics leveraging NET technology (Neutrophil Extracellular Traps technology) [6]Likely immuno-oncology modalities at interface of immunology and cancer biology [1][3]
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Extrinsic Immunity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Extrinsic Immunity Therapeutics.